Intent-to-treat analysis in the presence of off-treatment or missing data

Pharmaceutical Statistics

Volumn 10, Issue 3, 2011, Pages 191-195

  Keene, Oliver N ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

intent to treat; missing data; MMRM; per protocol; withdrawals

Indexed keywords

FLUTICASONE PROPIONATE; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

ADD ON THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); DISEASE EXACERBATION; DRUG EFFICACY; DRUG UTILIZATION; DRUG WITHDRAWAL; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS;

BIAS (EPIDEMIOLOGY); CLINICAL PROTOCOLS; DRUG TOXICITY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; STATISTICS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 79956085875     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.421     Document Type: Article

References (17)

1. Moher D, Schulz KF, Altman D, and for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001; 285 (15): 1987-1991. (Pubitemid 32366951)
2. Altman DG, Schulz KF, Moher D, et al,. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Annals of Internal Medicine 2001; 134 (8): 663-694. (Pubitemid 32322245)
3. ICH. Statistical principles for clinical trials. Statistics in Medicine 1999; 18: 1905-1942.
4. Lewis JA, Machin D,. Intention to treat-who should use ITT? British Journal of Cancer 1993; 68: 647-650. (Pubitemid 23301261)
5. Suissa S, Ernst P, Vandemheen KL, Aaron SD,. Methodological issues in therapeutic trials of COPD. European Respiratory Journal 2008; 31 (5): 1-8.
6. Lachin JM,. Statistical considerations in the intent-to-treat principle. Controlled Clinical Trials 2000; 21: 167-189. (Pubitemid 30259147)
7. Ellenberg JH,. Intent-to-treat analysis versus as-treated analysis. Drug Information Journal 1996; 30: 535-544. (Pubitemid 26154155)
8. CPMP. Points to consider on missing data. EMEA, London, 2001. Available at: (accessed 8 Dec 2008).
9. Schwartz D, Lellouch J,. Explanatory and pragmatic attitudes in therapeutical trials. Journal of Chronic Disease 1967; 20: 637-648.
10. Aaron SD, Vandemheen K, Fergusson D, et al,. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine 2007; 146 (8): 545-555. (Pubitemid 351650535)
11. Aaron SD, Fergusson D, Marks GB, et al,. Counting, analyzing and reporting exacerbations of COPD in randomized, controlled trials. Thorax 2008; 63: 122-128. (Pubitemid 351236474)
12. Tappenden P, Chilcott J, Ward S, Eggington S, Hind D, Hummel S,. Methodological issues in the economic analysis of cancer treatments. European Journal of Cancer 2006; 17: 2867-2875. (Pubitemid 44667482)
13. The BIG 1-98 Collaborative group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. New England Journal of Medicine 2009; 361: 766-776.
14. White IR,. Uses and limitations of randomization-based efficacy estimators. Statistical Methods in Medical Research 2005; 14: 327-347. (Pubitemid 41300810)
15. Greenland S, Lanes S, Jara M,. Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and G-estimation. Clinical Trials 2008; 5: 5-13. (Pubitemid 351412366)
16. Mallinckrodt CH, Lane PW, Schnell D, Peng Y, Mancuso JP,. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Information Journal 2008; 42: 303-319.
17. Carpenter JR, Kenward MG,. Missing data in clinical trials-a practical guide. National Health Service Co-ordinating Centre for Research Methodology, Birmingham. Available at: (accessed 27 Nov 2008).